Coronaviruses-drug discovery and therapeutic options

Nature Reviews Drug Discovery

Volumn 15, Issue 5, 2016, Pages 327-347

  Zumla, Alimuddin ^a   Chan, Jasper F W ^b   Azhar, Esam I ^c   Hui, David S C ^d   Yuen, Kwok Yung ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA1 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BETA1A INTERFERON; CORTICOSTEROID; ENFUVIRTIDE; GALIDESIVIR; GRIFFITHSIN; GRL 0617; HYDROCORTISONE; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; JL 103; K 22; LJ 001; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RIBAVIRIN; RIBOZYME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL FEATURE; COMMON COLD; CORONAVIRIDAE; CORONAVIRUS INFECTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EPIDEMIC; HUMAN; HUMAN CORONAVIRUS 229E; HUMAN CORONAVIRUS HKU1; HUMAN CORONAVIRUS NL63; HUMAN CORONAVIRUS OC43; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PLASMA TRANSFUSION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INHIBITION; CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFECTS; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

ANTIVIRAL AGENTS; CORONAVIRUS; DRUG DISCOVERY; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 84957818744     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.37     Document Type: Review

References (298)

1. Woo, P. C., Lau, S. K., Huang, Y., Yuen, K. Y. Coronavirus diversity, phylogeny and interspecies jumping. Exp. Biol. Med. (Maywood) 234, 1117-1127 (2009).
2. Chan, J. F. et al. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J. Infect. 65, 477-489 (2012).
3. Chan, J. F., Lau, S. K., Woo, P. C. The emerging novel Middle East respiratory syndrome coronavirus: the 'knowns' and 'unknowns'. J. Formos. Med. Assoc. 112, 372-381 (2013).
4. Chan, J. F., To, K. K., Tse, H., Jin, D. Y., Yuen, K. Y. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 21, 544-555 (2013).
5. Chan, J. F., To, K. K., Chen, H., Yuen, K. Y. Cross-species transmission and emergence of novel viruses from birds. Curr. Opin. Virol. 10, 63-69 (2015).
6. Woo, P. C. et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J. Virol. 86, 3995-4008 (2012).
7. Lau, S. K. et al. Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A. J. Virol. 89, 3076-3092 (2015).
8. Cheng, V. C., Lau, S. K., Woo, P. C., Yuen, K. Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20, 660-694 (2007).
9. Chan, J. F. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465-522 (2015).
10. Lee, N. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986-1994 (2003).
11. Tsang, K. W. et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1977-1985 (2003).
12. Zhao, Z. et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J. Med. Microbiol. 52, 715-720 (2003).
13. Xu, R. H. et al. Epidemiologic clues to SARS origin in China. Emerg. Infect. Dis. 10, 1030-1037 (2004).
14. Peiris, J. S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003).
15. Kuiken, T. et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263-270 (2003).
16. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003).
17. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
18. Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767-1772 (2003).
19. Woo, P. C. et al. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet 363, 841-845 (2004).
20. Hsu, L. Y. et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg. Infect. Dis. 9, 713-717 (2003).
21. Booth, C. M. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289, 2801-2809 (2003).
22. Wong, R. S., Hui, D. S. Index patient and SARS outbreak in Hong Kong. Emerg. Infect. Dis. 10, 339-341 (2004).
23. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. WHO emergencies preparedness, response http://www.who.int/csr/sars/country/table2004-04-21/en/[online]
24. Du, L. et al. Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China. Zhonghua Liu Xing Bing Xue Za Zhi 25, 925-928 (in Chinese) (2004).
25. Guan, Y. et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276-278 (2003).
26. Wang, M. et al. SARS-CoV infection in a restaurant from palm civet. Emerg. Infect. Dis. 11, 1860-1865 (2005).
27. Song, H. D. et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl Acad. Sci. USA 102, 2430-2435 (2005).
28. Tu, C. et al. Antibodies to SARS coronavirus in civets. Emerg. Infect. Dis. 10, 2244-2248 (2004).
29. Lau, S. K. et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl Acad. Sci. USA 102, 14040-14045 (2005).
30. Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676-679 (2005).
31. Ge, X. Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535-538 (2013).
32. He, B. et al. Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in China. J. Virol. 88, 7070-7082 (2014).
33. Woo, P. C., Lau, S. K., Yuen, K. Y. Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections. Curr. Opin. Infect. Dis. 19, 401-407 (2006).
34. Shi, Z., Hu, Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 133, 74-87 (2008).
35. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814-1820 (2012).
36. de Groot, R. J. et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 87, 7790-7792 (2013).
37. Hijawi, B. et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East. Mediterr. Health J. 19, S12-S18 (2013).
38. Hui, D. S., Perlman, S., Zumla, A. Spread of MERS to South Korea and China. Lancet Respir. Med. 3, 509-510 (2015).
39. World Health Organization. Middle East Respiratory Syndrome coronavirus (MERS-CoV)-Jordan [online], http://www.who.int/csr/don/01-october-2015-mers-jordan/en/(2015).
40. Woo, P. C. et al. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J. Virol. 81, 1574-1585 (2007).
41. Reusken, C. B. et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 13, 859-866 (2013).
42. Haagmans, B. L. et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 14, 140-145 (2014).
43. Azhar, E. I. et al. Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 370, 2499-2505 (2014).
44. Lau, S. K. et al. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J. Virol. 87, 8638-8650 (2013).
45. Corman, V. M. et al. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J. Virol. 88, 11297-11303 (2014).
46. Wang, Q. et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe 16, 328-337 (2014).
47. Wernery, U. et al. Acute middle East respiratory syndrome coronavirus infection in livestock Dromedaries, Dubai, 2014. Emerg. Infect. Dis. 21, 1019-1022 (2015).
48. Penttinen, P. M. et al. Taking stock of the first 133 MERS coronavirus cases globally-is the epidemic changing? Euro Surveill. 18, 20596 (2013).
49. Muller, M. A. et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect. Dis. 15, 559-564 (2015).
50. Assiri, A. et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369, 407-416 (2013).
51. Al-Abdallat, M. M. et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin. Infect. Dis. 59, 1225-1233 (2014).
52. Memish, Z. A., Zumla, A. I., Al-Hakeem, R. F., Al-Rabeeah, A. A., Stephens, G. M. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 368, 2487-2494 (2013).
53. Health Protection Agency. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill. 18, 20427 (2013).
54. Oboho, I. K. et al. 2014 MERS-CoV outbreak in Jeddah-a link to health care facilities. N. Engl. J. Med. 372, 846-854 (2015).
55. Hui, D. S., Peiris, M. Middle East respiratory syndrome. Am. J. Respir. Crit. Care Med. 192, 278-279 (2015).
56. Zumla, A., Hui, D. S., Perlman, S. Middle East respiratory syndrome. Lancet 386, 995-1007 (2015).
57. Hui, D. S., Zumla, A. Advancing priority research on the Middle East respiratory syndrome coronavirus. J. Infect. Dis. 209, 173-176 (2014).
58. Hui, D. S., Memish, Z. A., Zumla, A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr. Opin. Pulm. Med. 20, 233-241 (2014).
59. Arabi, Y. M. et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann. Intern. Med. 160, 389-397 (2014).
60. Assiri, A. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13, 752-761 (2013).
61. Eckerle, I., Muller, M. A., Kallies, S., Gotthardt, D. N., Drosten, C. In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection. Virol. J. 10, 359 (2013).
62. Saad, M. et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int. J. Infect. Dis. 29, 301-306 (2014).
63. Al-Tawfiq, J. A. et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin. Infect. Dis. 59, 160-165 (2014).
64. Drosten, C. et al. Transmission of MERS-coronavirus in household contacts. N. Engl. J. Med. 371, 828-835 (2014).
65. Breban, R., Riou, J., Fontanet, A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 382, 694-699 (2013).
66. Cauchemez, S. et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect. Dis.14, 50-56 (2014).
67. Poletto, C. et al. Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach. Euro Surveill. 19, 20824 (2014).
68. Anderson, R. M. et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 1091-1105 (2004).
69. Wallinga, J., Teunis, P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am. J. Epidemiol. 160, 509-516 (2004).
70. Cotten, M. et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 382, 1993-2002 (2013).
71. Cotten, M. et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio 5, e01062-13 (2014).
72. Hui, D. S., Sung, J. J. Severe acute respiratory syndrome. Chest 124, 12-15 (2003).
73. Cheng, V. C., Tang, B. S., Wu, A. K., Chu, C. M., Yuen, K. Y. Medical treatment of viral pneumonia including SARS in immunocompetent adult. J. Infect. 49, 262-273 (2004).
74. Cheng, V. C., Chan, J. F., To, K. K., Yuen, K. Y. Clinical management and infection control of SARS: lessons learned. Antiviral Res. 100, 407-419 (2013).
75. Wong, S. S., Yuen, K. Y. The management of coronavirus infections with particular reference to SARS. J. Antimicrob. Chemother. 62, 437-441 (2008).
76. Chan, K. S. et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J. 9, 399-406 (2003).
77. Chu, C. M. et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252-256 (2004).
78. Loutfy, M. R. et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290, 3222-3228 (2003).
79. Wang, H. et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N. Engl. J. Med. 349, 507-508 (2003).
80. Griffith, J. F. et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 235, 168-175 (2005).
81. Tsang, O. T. et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg. Infect. Dis. 9, 1381-1387 (2003).
82. Lee, N. et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J. Clin. Virol. 31, 304-309 (2004).
83. Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44-46 (2005).
84. Soo, Y. O. et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin. Microbiol. Infect. 10, 676-678 (2004).
85. Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80-90 (2015).
86. Omrani, A. S. et al. Ribavirin and interferon?-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 14, 1090-1095 (2014).
87. Al-Tawfiq, J. A., Momattin, H., Dib, J., Memish, Z. A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 20, 42-46 (2014).
88. Khalid, M. et al. Ribavirin and interferon-?-2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases. Antivir. Ther. 20, 87-91 (2015).
89. Shalhoub, S. et al. IFN-?2a or IFN-?1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J. Antimicrob. Chemother. 70, 2129-2132 (2015).
90. Spanakis, N. et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int. J. Antimicrob. Agents 44, 528-532 (2014).
91. van Boheemen, S. et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3, e00473-12 (2012).
92. Lu, L. et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014).
93. Gao, J. et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J. Virol. 87, 13134-13140 (2013).
94. Jiang, L. et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 6, 234ra59 (2014).
95. Ying, T. et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796-7805 (2014).
96. Tang, X. C. et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl Acad. Sci. USA 111, E2018-E2026 (2014).
97. Du, L. et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in middle East respiratory syndrome coronavirus spike protein. J. Virol. 88, 7045-7053 (2014).
98. Yuan, K. et al. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem. Biophys. Res. Commun. 319, 746-752 (2004).
99. Channappanavar, R. et al. Protective effect of intranasal regimens containing peptidic Middle East Respiratory Syndrome coronavirus fusion inhibitor against MERS-CoV infection. J. Infect. Dis. 212, 1894-1903 (2003).
100. Pascal, K. E. et al. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 112, 8738-8743 (2015).
101. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454 (2003).
102. Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254 (2013).
103. Huang, X. et al. Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J. Virol. 89, 7202-7213 (2015).
104. Yeager, C. L. et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357, 420-422 (1992).
105. Vlasak, R., Luytjes, W., Spaan, W., Palese, P. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc. Natl Acad. Sci. USA 85, 4526-4529 (1988).
106. Hofmann, H. et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl Acad. Sci. USA 102, 7988-7993 (2005).
107. Gierer, S. et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J. Virol. 87, 5502-5511 (2013).
108. Qian, Z., Dominguez, S. R., Holmes, K. V. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS ONE 8, e76469 (2013).
109. Shirato, K., Kawase, M., Matsuyama, S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87, 12552-12561 (2013).
110. Millet, J. K., Whittaker, G. R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl Acad. Sci. USA 111, 15214-15219 (2014).
111. Zhou, Y. et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 116, 76-84 (2015).
112. Lundin, A. et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. PLoS Pathog. 10, e1004166 (2014).
113. Knoops, K. et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 6, e226 (2008).
114. Barnard, D. L., Kumaki, Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol. 6, 615-631 (2011).
115. Kilianski, A., Baker, S. C. Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors. Antiviral Res. 101, 105-112 (2014).
116. Cinatl, J. et al. Treatment of SARS with human interferons. Lancet 362, 293-294 (2003).
117. So, L. K. et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 361, 1615-1617 (2003).
118. Pfefferle, S. et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7, e1002331 (2011).
119. de Wilde, A. H. et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-? treatment. J. Gen. Virol. 94, 1749-1760 (2013).
120. Tanaka, Y., Sato, Y., Sasaki, T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses 5, 1250-1260 (2013).
121. Falzarano, D. et al. Inhibition of novel ? coronavirus replication by a combination of interferon-?2b and ribavirin. Sci. Rep. 3, 1686 (2013).
122. Chan, J. F. et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67, 606-616 (2013).
123. de Wilde, A. H. et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875-4884 (2014).
124. Dyall, J. et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885-4893 (2014).
125. Kindrachuk, J. et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob. Agents Chemother. 59, 1088-1099 (2015).
126. Liu, Q. et al. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for their ability to block viral entry. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.03977-14 (2014).
127. Elshabrawy, H. A. et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J. Virol. 88, 4353-4365 (2014).
128. Chan, J. F. et al. Treatment with lopinavir/ritonavir or interferon-?1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset. J. Infect. Dis. 212, 1904-1913 (2015).
129. Faure, E. et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS ONE 9, e88716 (2014).
130. AlGhamdi, M., Mushtaq, F., Awn, N., Shalhoub, S. MERS CoV infection in two renal transplant recipients: case report. Am. J. Transplant. 15, 1101-1104 (2015).
131. Fukushima, A. et al. Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus. Intervirology 52, 92-99 (2009).
132. Rider, T. H. et al. Broad-spectrum antiviral therapeutics. PLoS ONE 6, e22572 (2011).
133. Mielech, A. M., Kilianski, A., Baez-Santos, Y. M., Mesecar, A. D., Baker, S. C. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology 450-451, 64-70 (2014).
134. Barretto, N. et al. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. 79, 15189-15198 (2005).
135. Mielech, A. M., Chen, Y., Mesecar, A. D., Baker, S. C. Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities. Virus Res. 194, 184-190 (2014).
136. Hilgenfeld, R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 281, 4085-4096 (2014).
137. Baez-Santos, Y. M., St John, S. E., Mesecar, A. D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21-38 (2015).
138. Baez-Santos, Y. M. et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J. Med. Chem. 57, 2393-2412 (2014).
139. Ratia, K. et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl Acad. Sci. USA 105, 16119-16124 (2008).
140. Lee, H. et al. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem. Biol. 10, 1456-1465 (2015).
141. Chaudhuri, R. et al. Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications. J. Mol. Biol. 414, 272-288 (2011).
142. Adedeji, A. O., Sarafianos, S. G. Antiviral drugs specific for coronaviruses in preclinical development. Curr. Opin. Virol. 8, 45-53 (2014).
143. Yang, H. et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3, e324 (2005).
144. Ren, Z. et al. The newly emerged SARS-like coronavirus HCoV-EMC also has an 'Achilles' heel': current effective inhibitor targeting a 3C-like protease. Protein Cell 4, 248-250 (2013).
145. Chen, F. et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 31, 69-75 (2004).
146. Nukoolkarn, V., Lee, V. S., Malaisree, M., Aruksakulwong, O., Hannongbua, S. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CLpro inhibitors. J. Theor. Biol. 254, 861-867 (2008).
147. Olschlager, S., Neyts, J., Gunther, S. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res. 91, 89-93 (2011).
148. Falzarano, D. et al. Treatment with interferon-?2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19, 1313-1317 (2013).
149. Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405 (2014).
150. Peters, H. L. et al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorg. Med. Chem. Lett. 25, 2923-2926 (2015).
151. Lu, A. et al. Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. Virology 324, 84-89 (2004).
152. Wang, Z. et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J. Virol. 78, 7523-7527 (2004).
153. Tanner, J. A. et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem. Biol. 12, 303-311 (2005).
154. Kim, M. K. et al. 2,6-bis-arylmethyloxy-5-hydroxychro mones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). Eur. J. Med. Chem. 46, 5698-5704 (2011).
155. Adedeji, A. O. et al. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob. Agents Chemother. 56, 4718-4728 (2012).
156. Adedeji, A. O. et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob. Agents Chemother. 58, 4894-4898 (2014).
157. Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl Acad. Sci. USA 111, 4970-4975 (2014).
158. Yang, Z. Y. et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl Acad. Sci. USA 102, 797-801 (2005).
159. Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672-12676 (2004).
160. Coughlin, M. M., Prabhakar, B. S. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev. Med. Virol. 22, 2-17 (2012).
161. Li, Y. et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25, 1237-1249 (2015).
162. Corti, D. et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl Acad. Sci. USA 112, 10473-10478 (2015).
163. Sainz, B. et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res. 120, 146-155 (2006).
164. Zheng, B. J. et al. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antiviral Ther. 10, 393-403 (2005).
165. Liu, I. J. et al. Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. Antiviral Res. 81, 82-87 (2009).
166. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302-1307 (1998).
167. Greenberg, M. L., Cammack, N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54, 333-340 (2004).
168. Izumi, K. et al. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. Int. J. Biochem. Cell Biol. 45, 908-915 (2013).
169. Zhang, Y. et al. Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett. 560, 141-146 (2004).
170. Wu, C. J., Huang, H. W., Liu, C. Y., Hong, C. F., Chan, Y. L. Inhibition of SARS-CoV replication by siRNA. Antiviral Res. 65, 45-48 (2005).
171. Tang, Q., Li, B., Woodle, M., Lu, P. Y. Application of siRNA against SARS in the rhesus macaque model. Methods Mol. Biol. 442, 139-158 (2008).
172. Li, B. J. et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 11, 944-951 (2005).
173. O'Keefe, B. R. et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 84, 2511-2521 (2010).
174. Barton, C. et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob. Agents Chemother. 58, 120-127 (2014).
175. Yang, Y. et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4, 951-961 (2013).
176. Cui, L. et al. The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells. J. Virol. 89, 9029-9043 (2015).
177. Niemeyer, D. et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J. Virol. 87, 12489-12495 (2013).
178. Siu, K. L. et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J. Virol. 88, 4866-4876 (2014).
179. He, M. L. et al. Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication. Hong Kong Med. J. 3 (Suppl. 4), 28-31 (2009).
180. Akerstrom, S., Mirazimi, A., Tan, Y. J. Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. Antiviral Res. 73, 219-227 (2007).
181. Pervushin, K. et al. Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog. 5, e1000511 (2009).
182. Wilson, L., Gage, P., Ewart, G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 353, 294-306 (2006).
183. Lin, S. Y. et al. Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target. J. Med. Chem. 57, 2247-2257 (2014).
184. Wolf, M. C. et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl Acad. Sci. USA 107, 3157-3162 (2010).
185. Vigant, F. et al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog. 9, e1003297 (2013).
186. Hollmann, A., Castanho, M. A., Lee, B., Santos, N. C. Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors. Biochem. J. 459, 161-170 (2014).
187. Hollmann, A. et al. Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture. Nanomedicine 11, 1163-1167 (2015).
188. Menachery, V. D. et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. mBio 5, e01174-e01114 (2014).
189. Lau, S. K. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J. Gen. Virol. 94, 2679-2690 (2013).
190. Josset, L. et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 4, e00165-e00113 (2013).
191. Haagmans, B. L. et al. Pegylated interferon-? protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10, 290-293 (2004).
192. Hart, B. J. et al. Interferon-? and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 95, 571-577 (2014).
193. Rosenfeld, M. R. et al. A multi-institution Phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 12, 1071-1077 (2010).
194. Okada, H. et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with ?-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29, 330-336 (2011).
195. Rossignol, J. F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 110, 94-103 (2014).
196. Haffizulla, J. et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, Phase 2b/3 trial. Lancet Infect. Dis. 14, 609-618 (2014).
197. Rossignol, J. F., Kabil, S. M., El-Gohary, Y., Elfert, A., Keeffe, E. B. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther. 28, 574-580 (2008).
198. Wohlford-Lenane, C. L. et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J. Virol. 83, 11385-11390 (2009).
199. Wiley, J. A. et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS ONE 4, e7142 (2009).
200. Carbajo-Lozoya, J. et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res. 184, 44-53 (2014).
201. Ohnuma, K. et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J. Virol. 87, 13892-13899 (2013).
202. Huentelman, M. J. et al. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension 44, 903-906 (2004).
203. Han, D. P., Penn-Nicholson, A., Cho, M. W. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology 350, 15-25 (2006).
204. Chen, Y. T. et al. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Negl. Trop. Dis. 4, e825 (2010).
205. Ndao, M. et al. A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection. Antimicrob. Agents Chemother. 57, 6063-6073 (2013).
206. Vermeire, J. J., Lantz, L. D., Caffrey, C. R. Cure of hookworm infection with a cysteine protease inhibitor. PLoS Negl. Trop. Dis. 6, e1680 (2012).
207. Sai, J. K. et al. Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. J. Gastroenterol. 45, 335-341 (2010).
208. Talukdar, R., Tandon, R. K. Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J. Gastroenterol. Hepatol. 23, 34-41 (2008).
209. Burkard, C. et al. ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. J. Virol. 89, 4434-4448 (2015).
210. Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., Cauda, R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect. Dis. 3, 722-727 (2003).
211. Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., Van Ranst, M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 323, 264-268 (2004).
212. Vincent, M. J. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69 (2005).
213. Kono, M. et al. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 77, 150-152 (2008).
214. Madrid, P. B. et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PloS ONE 8, e60579 (2013).
215. Barnard, D. L. et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antiviral Chem. Chemother. 17, 275-284 (2006).
216. Zhang, N., Jiang, S., Du, L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines 13, 761-774 (2014).
217. Papaneri, A. B. et al. Middle East respiratory syndrome: obstacles and prospects for vaccine development. Expert Rev. Vaccines 14, 949-962 (2015).
218. Almazan, F. et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 4, e00650-00613 (2013).
219. Wang, L. et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6, 7712 (2015).
220. Song, F. et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 87, 11950-11954 (2013).
221. Volz, A. et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J. Virol. 89, 8651-8656 (2015).
222. Kim, E. et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 32, 5975-5982 (2014).
223. Guo, X. et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 145, 476-484 (2015).
224. Czub, M., Weingartl, H., Czub, S., He, R., Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273-2279 (2005).
225. Coleman, C. M. et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32, 3169-3174 (2014).
226. Zhao, G. et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol. J. 10, 266 (2013).
227. Du, L. et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87, 9939-9942 (2013).
228. Mou, H. et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87, 9379-9383 (2013).
229. Du, L. et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PloS ONE 8, e81587 (2013).
230. Ma, C. et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 32, 2100-2108 (2014).
231. Ma, C. et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-The importance of immunofocusing in subunit vaccine design. Vaccine 32, 6170-6176 (2014).
232. Lan, J. et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PloS ONE 9, e112602 (2014).
233. Zhang, N. et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell. Mol. Immunol. http://dx.doi.org/10.1038/cmi.2015.03 (2015).
234. Lassnig, C. et al. Development of a transgenic mouse model susceptible to human coronavirus 229E. Proc. Natl Acad. Sci. USA 102, 8275-8280 (2005).
235. Dijkman, R. et al. Seroconversion to HCoV-NL63 in rhesus macaques. Viruses 1, 647-656 (2009).
236. Jacomy, H., Fragoso, G., Almazan, G., Mushynski, W. E., Talbot, P. J. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice. Virology 349, 335-346 (2006).
237. Sutton, T. C., Subbarao, K. Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus. Virology 479-480, 247-258 (2015).
238. Fouchier, R. A. et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240 (2003).
239. McCray, P. B. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813-821 (2007).
240. Tseng, C. T. et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J. Virol. 81, 1162-1173 (2007).
241. Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3, e5 (2007).
242. Munster, V. J., de Wit, E., Feldmann, H. Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 368, 1560-1562 (2013).
243. Yao, Y. et al. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J. Infect. Dis. 209, 236-242 (2014).
244. Falzarano, D. et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 10, e1004250 (2014).
245. Raj, V. S. et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J. Virol. 88, 1834-1838 (2014).
246. de Wit, E. et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One. 8, e69127 (2013).
247. Coleman, C. M., Matthews, K. L., Goicochea, L., Frieman, M. B. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J. General Virol. 95, 408-412 (2014).
248. Agrawal, A. S. et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89, 3659-3670 (2015).
249. Hung, I. F. et al. Viral loads in clinical specimens and SARS manifestations. Emerg. Infect. Dis. 10, 1550-1557 (2004).
250. Abd El Wahed, A., Patel, P., Heidenreich, D., Hufert, F. T., Weidmann, M. Reverse transcription recombinase polymerase amplification assay for the detection of middle East respiratory syndrome coronavirus. PLoS Curr. 5, currents.outbreaks. 62df1c7c75ffc96cd59034531e2e8364 (2013).
251. Shirato, K. et al. Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Virol. J. 11, 139 (2014).
252. Song, D. et al. Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels. J. Clin. Microbiol. 53, 1178-1182 (2015).
253. Chen, Y. et al. A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerg. Microbes Infect. 4, e26 (2015).
254. Sridhar, S. et al. A systematic approach to novel virus discovery in emerging infectious disease outbreaks. J. Mol. Diagn. 17, 230-241 (2015).
255. Corman, V. M. et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill. 17, 20334 (2012).
256. Corman, V. M. et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 17, 20285 (2012).
257. Chan, J. F. et al. Development and evaluation of novel real-time RT-PCR assays with locked nucleic acid probes targeting the leader sequences of human pathogenic coronaviruses. J. Clin. Microbiol. 53, 2722-2726 (2015).
258. Chan, J. F. et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 207, 1743-1752 (2013).
259. Pyrc, K. et al. Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. J. Virol. 84, 11255-11263 (2010).
260. Dijkman, R. et al. Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism. J. Virol. 87, 6081-6090 (2013).
261. Dominguez, S. R., Travanty, E. A., Qian, Z., Mason, R. J. Human coronavirus HKU1 infection of primary human type II alveolar epithelial cells: cytopathic effects and innate immune response. PLoS ONE 8, e70129 (2013).
262. Dominguez, S. R. et al. Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses. J. General Virol. 95, 836-848 (2014).
263. Zhou, J. et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J. Infect. Dis. 209, 1331-1342 (2014).
264. Chu, H. et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiv380 (2015).
265. Chu, H. et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 454-455, 197-205 (2014).
266. Chan, R. W. et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J. Virol. 87, 6604-6614 (2013).
267. Chan, R. W. et al. Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study. Lancet Respir.Med. 2, 813-822 (2014).
268. Muller, M. A. et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. mBio 3, e00515-12 (2012).
269. Eckerle, I. et al. Replicative capacity of MERS coronavirus in livestock cell lines. Emerg. Infect. Dis. 20, 276-279 (2014).
270. Chan, K. H. et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J. Infect. 67, 130-140 (2013).
271. Perera, R. A. et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. 18, 20574 (2013).
272. Hung, I. F. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144, 464-473 (2013).
273. Hung, I. F. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52, 447-456 (2011).
274. WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 5, ecurrents.outbreaks. 0bf719e352e7478f8ad85fa30127ddb8 (2013).
275. Kilianski, A., Mielech, A. M., Deng, X., Baker, S. C. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. J. Virol. 87, 11955-11962 (2013).
276. Agnihothram, S. et al. A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. mBio 5, e00047-00014 (2014).
277. Reichard, O., Yun, Z. B., Sonnerborg, A., Weiland, O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J. Med. Virol. 41, 99-102 (1993).
278. Hall, C. B., Walsh, E. E., Hruska, J. F., Betts, R. F., Hall, W. J. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA 249, 2666-2670 (1983).
279. Ascioglu, S., Leblebicioglu, H., Vahaboglu, H., Chan, K. A. Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J. Antimicrob. Chemother. 66, 1215-1222 (2011).
280. Bausch, D. G., Hadi, C. M., Khan, S. H., Lertora, J. J. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin. Infect. Dis. 51, 1435-1441 (2010).
281. Lee, C. et al. Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase. Bioorg. Med. Chem. Lett. 19, 1636-1638 (2009).
282. Liao, H. I. et al. mRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein. J. Biol. Chem. 284, 17512-17520 (2009).
283. Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl Acad. Sci. USA 102, 11876-11881 (2005).
284. Hatesuer, B. et al. Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. PLoS Pathog. 9, e1003774 (2013).
285. Abe, M. et al. TMPRSS2 is an activating protease for respiratory parainfluenza viruses. J. Virol. 87, 11930-11935 (2013).
286. Bertram, S. et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J. Virol. 87, 6150-6160 (2013).
287. Lokugamage, K. G. et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 26, 797-808 (2008).
288. Lu, X. et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 122, 496-502 (2007).
289. See, R. H. et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. General Virol. 87, 641-650 (2006).
290. Spruth, M. et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24, 652-661 (2006).
291. Qin, E. et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 24, 1028-1034 (2006).
292. Zhou, J. et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23, 3202-3209 (2005).
293. Lamirande, E. W. et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 82, 7721-7724 (2008).
294. Netland, J. et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399, 120-128 (2010).
295. Fett, C., DeDiego, M. L., Regla-Nava, J. A., Enjuanes, L., Perlman, S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 87, 6551-6559 (2013).
296. Stadler, K. et al. SARS-beginning to understand a new virus. Nat. Rev. Microbiol. 1, 209-218 (2003).
297. Peiris, J. S., Guan, Y., Yuen, K. Y. Severe acute respiratory syndrome. Nat. Med. 10, (Suppl. 12), 88-97 (2004).
298. Haagmans, B. L. et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 351, 77-81 (2016).